8-K/A: Flora Growth Corp. Completes Acquisition of TruHC Pharma GmbH, Files Amended 8-K

Flora Growth Corp. has finalized the first stage of its acquisition of TruHC Pharma GmbH, filing an amended 8-K to include historical financials and pro forma information.

Summary

• Flora Growth Corp. completed the first closing of its acquisition of TruHC Pharma GmbH.
• This acquisition was initially reported in a Form 8-K filed on April 23, 2024.
• The amended 8-K/A includes TruHC's historical financial statements and unaudited pro forma condensed combined financial information.
• The financial statements of TruHC include audited results for the year ended December 31, 2023, and unaudited results for the three months ended March 31, 2024.
• The pro forma financial information combines the financials of Flora Growth Corp. and TruHC Pharma GmbH.
• The acquisition involved the issuance of 2,135,199 Flora Growth Corp. common shares at the first closing.
• An additional 635,363 shares will be issued upon shareholder approval at a future meeting.
• TruHC's loans from TruHC Holding GmbH were forgiven in April 2024.

Sentiment

Score: 4

Explanation: The document highlights significant financial losses and going concern issues for TruHC, which are negative indicators. While the acquisition itself is a positive strategic move for Flora, the financial health of the acquired entity is concerning.

Positives

• The acquisition of TruHC Pharma GmbH expands Flora Growth Corp.'s presence in the European cannabis market.
• The forgiveness of TruHC's loans by TruHC Holding GmbH improves TruHC's financial position.
• The pro forma statements provide a clear picture of the combined entity's financial position.

Negatives

• TruHC has incurred significant net losses, with a loss of 371,787 Euros in 2023 and 105,572 Euros in the first three months of 2024.
• TruHC's financial statements raise substantial doubt about its ability to continue as a going concern.
• The pro forma statements show a consolidated net loss of $3.676 million for the three months ended March 31, 2024, and $57.497 million for the year ended December 31, 2023.

Risks

• TruHC's ability to continue as a going concern is dependent on obtaining additional capital.
• The actual amount of capital that can be raised is uncertain and depends on market conditions.
• There is no assurance that additional financing will be available on favorable terms or at all.
• The final purchase price allocation may differ materially from the preliminary allocation.
• The combined company may face challenges integrating TruHC's operations and managing its financial performance.

Future Outlook

The document indicates that the second closing of the acquisition is expected to occur in August 2024, pending shareholder approval. The company is evaluating cost reductions and other alternatives to address its going concern issues and may seek additional funding through various means.

Management Comments

• Management is currently evaluating various cost reductions and other alternatives.
• Management may seek to raise additional funds through the issuance of equity, debt securities, through arrangements with strategic partners or, through obtaining credit from financial institutions and the possible disposition of assets or otherwise.

Industry Context

This acquisition reflects a trend of consolidation in the cannabis industry, with companies seeking to expand their market presence and access new geographies. Flora's acquisition of TruHC provides it with a foothold in the German medical cannabis market, which is a significant market in Europe.

Comparison to Industry Standards

• The financial performance of TruHC, with its significant losses and going concern issues, is not uncommon for early-stage cannabis companies, particularly those focused on the European market.
• Compared to established players in the global cannabis market, TruHC's revenue is likely very small, and its losses are significant relative to its size.
• The pro forma financials show that the combined entity is still loss-making, which is not unusual for companies in the growth phase of the cannabis industry.
• The acquisition of TruHC by Flora is similar to other acquisitions in the cannabis sector where larger companies acquire smaller companies to gain access to specific markets, licenses, or technologies.

Related Party Transactions

• TruHC had significant loan agreements with TruHC Holding GmbH, which were forgiven in April 2024.

Stakeholder Impact

• Shareholders of Flora Growth Corp. will be impacted by the dilution from the issuance of new shares for the acquisition.
• Employees of TruHC may experience changes as the company is integrated into Flora.
• Creditors of TruHC may be impacted by the forgiveness of the loans from TruHC Holding GmbH.
• Customers of TruHC may see changes in the products and services offered as a result of the acquisition.

Next Steps

• Flora Growth Corp. needs to obtain shareholder approval for the second closing of the acquisition.
• The company will need to integrate TruHC's operations into its existing business.
• Management will need to implement cost reductions and explore options for raising additional capital.
• The final purchase price allocation will be determined when the Company has completed the detailed valuations and necessary calculations.

Key Dates

Keywords

acquisition, cannabis, TruHC Pharma GmbH, Flora Growth Corp, financial statements, pro forma, medical cannabis, EU-GMP, Germany